Figure 4. PVSRIPO recruits innate immune cells into SUM149 and DU145 xenografts.

(A) SUM149 and DU145 cells were implanted in athymic nu/nu mice. Tumors were injected with 10⁸ pfu of PVSRIPO when they reached 150-200 mm³. Tumors were collected at 48 hours post injection and innate immune cell infiltration was assessed by flow cytometry (CD45.2, CD11b, F480, Ly6C, Ly6G, B220, CD335). The numbers reflect percentage of cells in the gated population (boxed area) in the preceding flow quadrant as indicated. Data are representative of three different experiments and a total of 15 mice per group. (B) Tumor infiltrating immune cell percentages from one representative experiment (n=5) in the SUM149 breast tumor model are shown. ***p<0.001. (C) Tumor infiltrating immune cell percentages from one representative experiment (n=5) in the DU145 prostate tumor model are shown. *p<0.05, **p<0.01, ***p<0.001.